Surge Therapeutics
Dr. Irvine is a pioneer in applying materials science to immunology. His interdisciplinary work at the intersection of bioengineering, drug delivery, and immunology is consistently at the forefront of its field, with regular publication in Nature, Nature Medicine, Nature Biotechnology, and Science Translational Medicine. He has received an NSF CAREER award and been named to Technology Review’s “TR35.” Dr. Irvine is a founder of Torque Therapeutics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Surge Therapeutics
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.